Lv7
4930 积分 2023-08-11 加入
MDM2-p53相互作用抑制剂的研究进展和临床现状
12天前
已完结
Developing SHP2-based combination therapy for KRAS-amplified cancer
2个月前
已关闭
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
2个月前
已完结
MEK-SHP2 inhibition prevents tibial pseudarthrosis caused by NF1 loss in Schwann cells and skeletal stem/progenitor cells
2个月前
已完结
Combating KRASG12C Inhibitor Resistance
2个月前
已完结
Targeting PDGFRA-SHP2 signaling enhances radiotherapy in IDH1-mutant glioma
2个月前
已完结
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2个月前
已完结
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
2个月前
已完结
A patent review of SHP2 allosteric inhibitors (2018-present)
2个月前
已完结
Targeting SHP2 Signaling in Lung Cancer
2个月前
已完结
皖公网安备34019202002308
